{"id":"2530b16b-507f-5af9-b048-d700aeb941d6","stable_key":"8b3cf083-ea9c-54f5-b42b-bf1fef5b2978:metformin-vatpase-inhibition","predicate":"inhibits","statement":"Clinically relevant concentrations of metformin inhibited the lysosomal proton pump v-ATPase, leading to AMPK activation without effects on cellular AMP levels.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"3c9a2c78-ac19-5d92-83d2-1db01009ddef","mechanism_event_label":"The energy sensor is switched on at the lysosome rather than by a fall in cellular AMP.","subject":{"id":"519971b1-5aef-5ad7-8022-840144855cd0","slug":"metformin","display_name":"Metformin","entity_type_key":"drug"},"object":{"id":"67e40703-2abe-5032-bb31-e14a8f750ea1","slug":"lysosomal-v-atpase","display_name":"Lysosomal vacuolar H+-ATPase (v-ATPase)","entity_type_key":"protein_complex"},"evidence_count":1,"mechanism_event":{"id":"3c9a2c78-ac19-5d92-83d2-1db01009ddef","stable_key":"8b3cf083-ea9c-54f5-b42b-bf1fef5b2978:metformin-vatpase-inhibition-event","event_type":"biochemical_relationship","label":"The energy sensor is switched on at the lysosome rather than by a fall in cellular AMP.","description":"Clinically relevant concentrations of metformin inhibited the lysosomal proton pump v-ATPase, leading to AMPK activation without effects on cellular AMP levels.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"3f80c230-5a0c-5f09-8627-4dcd191a49f9","slug":"lysosomal-ampk-activation","display_name":"Lysosome-associated AMPK activation","entity_type_key":"cellular_process"},"role":"downstream_process","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"d47321ac-44bb-5a88-afdb-6435b57a91b9","slug":"amp","display_name":"AMP","entity_type_key":"small_molecule"},"role":"unchanged_metabolite","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"519971b1-5aef-5ad7-8022-840144855cd0","slug":"metformin","display_name":"Metformin","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"67e40703-2abe-5032-bb31-e14a8f750ea1","slug":"lysosomal-v-atpase","display_name":"Lysosomal vacuolar H+-ATPase (v-ATPase)","entity_type_key":"protein_complex"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/metformin-research/35197629.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"587594a8bbbf0a2baa7066264c0c46b26ded6231287176608885e736bee36983\", \"start_char\": 0, \"end_char\": 1549, \"text_sha256\": \"587594a8bbbf0a2baa7066264c0c46b26ded6231287176608885e736bee36983\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Photoactive metformin probe, binding studies, knockouts in mice and C. elegans","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Clinically relevant low metformin concentrations; PEN2 knockout and ATP6AP1-binding mutants","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"A direct binding partner at low dose with a micromolar dissociation constant. Lifespan and fat-content endpoints are model endpoints, not clinical outcomes.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake.","comparator":null,"unit":null,"notes":"","entity":{"slug":"metformin","display_name":"Metformin","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human cells, mouse and C. elegans","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The energy sensor is switched on at the lysosome rather than by a fall in cellular AMP.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[metformin-p35197629] Low-dose metformin targets the lysosomal AMPK pathway through PEN2. (2022). https://pubmed.ncbi.nlm.nih.gov/35197629/ DOI: 10.1038/s41586-022-04431-8","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Lysosome, liver and intestine","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"246303e1-91fe-5442-bd06-a00fdc339fc1","evidence_kind":"source_excerpt","locator":"Lines 658-669","start_line":658,"end_line":669,"excerpt":"### metformin-vatpase-inhibition\nClinically relevant concentrations of metformin inhibited the lysosomal proton pump v-ATPase, leading to AMPK activation without effects on cellular AMP levels.\nCondition category: normal\nnutrient_topic: Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake.\nplain_language: The energy sensor is switched on at the lysosome rather than by a fall in cellular AMP.\norganism: Human cells, mouse and C. elegans\ntissue_or_cell_type: Lysosome, liver and intestine\nexperimental_model: Photoactive metformin probe, binding studies, knockouts in mice and C. elegans\nlimitations: A direct binding partner at low dose with a micromolar dissociation constant. Lifespan and fat-content endpoints are model endpoints, not clinical outcomes.\nexposure: Clinically relevant low metformin concentrations; PEN2 knockout and ATP6AP1-binding mutants\nevidence_span: {\"source_cache\": \"artifacts/metformin-research/35197629.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"587594a8bbbf0a2baa7066264c0c46b26ded6231287176608885e736bee36983\", \"start_char\": 0, \"end_char\": 1549, \"text_sha256\": \"587594a8bbbf0a2baa7066264c0c46b26ded6231287176608885e736bee36983\"}\n[metformin-p35197629] Low-dose metformin targets the lysosomal AMPK pathway through PEN2. (2022). https://pubmed.ncbi.nlm.nih.gov/35197629/ DOI: 10.1038/s41586-022-04431-8","model_system":"Photoactive metformin probe, binding studies, knockouts in mice and C. elegans","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [metformin-p35197629] Low-dose metformin targets the lysosomal AMPK pathway through PEN2. (2022). https://pubmed.ncbi.nlm.nih.gov/35197629/ DOI: 10.1038/s41586-022-04431-8","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"d0474bd9-7cfd-5695-a152-12f3633a6813","stable_key":"import-8b3cf083-ea9c-54f5-b42b-bf1fef5b2978","title":"Metformin: transport, molecular targets, gut mechanisms and nutrient interactions (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"0b51d0759aeeb88ac5b3a6277245a196b2bb024d7c32ec89379ed428fb06bfb5","revision_id":"0405c75e-f06e-5af7-a642-1777802f6004","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}